Author + information
- Charalambos Vlachopoulos,
- Dimitrios Terentes-Printzios,
- Dimitri Richter,
- Konstantinos Aznaouridis,
- Nikolaos Ioakeimidis and
- Christodoulos I Stefanadis
Initial studies on omega-3 polyunsuturated fatty acids (PUFAs) showed promising results on cardiovascular (CV) events. However, recent studies reported controversial Results. We aimed to perform a meta-analysis of all randomized studies that used omega-3 PUFA supplements and investigate their effect on CV mortality and events as well as the effect of dose on CV events.
The MEDLINE, Cochrane and EMBASE databases, and reviewing reference lists from retrieved articles were searched until September 2012. Randomized studies that reported relative risk (RR) estimates with 95% confidence intervals were included. Two reviewers extracted data independently and summary estimates of association were obtained using a fixed- or random-effects model.
Of the 17 studies included (63,495 participants, mean follow-up 2.7 years), 16 reported results on CV death (63,289 individuals) and all on total CV events. The pooled relative risks (RRs) for CV death and total CV events were 0.90 (95% CI: 0.84 to 0.96, p=0.002) and 0.94 (95% CI: 0.90-0.99, p=0.017). (Figure) When we applied a sensitivity analysis excluding 3 studies (asterisk, Figure) that used less than 0.85 grams per day of omega-3 PUFAs the RR for total CV events was 0.93 (95% CI: 0.87-0.98, p=0.008).
In conclusion, a modest beneficial effect of PUFA on total CV events and CV death is evident. A dose-dependent effect of PUFA on CV events is likely and warrants further investigation.
West, Room 3004
Sunday, March 10, 2013, 11:30 a.m.-11:45 a.m.
Session Title: Prevention: Clinical and Subclinical Cardiovascular Disease – Predicting Risk in 2013
Abstract Category: 24. Prevention: Clinical
Presentation Number: 928-6
- 2013 American College of Cardiology Foundation